Get the Stockscreener App
1.13
0.89%
0.010
After Hours:
1.10
-0.03
-2.65%
Pasithea Therapeutics Corp stock is traded at $1.13, with a volume of 365.57K.
It is up +0.89% in the last 24 hours and up +60.76% over the past month.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
See More
Previous Close:
$1.12
Open:
$1.12
24h Volume:
365.57K
Relative Volume:
0.06
Market Cap:
$25.31M
Revenue:
-
Net Income/Loss:
$-16.28M
P/E Ratio:
-0.0812
EPS:
-13.91
Net Cash Flow:
$-13.75M
1W Performance:
+0.00%
1M Performance:
+60.76%
6M Performance:
+36.28%
1Y Performance:
-57.68%
1-Day Range:
$1.09
$1.15
1-Week Range:
$1.09
$1.23
52-Week Range:
$0.281
$3.85
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Name
Pasithea Therapeutics Corp
Sector
Industry
Phone
(702) 514-4174
Address
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
1.13 | 25.09M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pasithea Therapeutics Corp Stock (KTTA) Latest News
Market Review: Is Pasithea Therapeutics Corp stock a contrarian buy2025 Top Gainers & Safe Capital Allocation Plans - moha.gov.vn
JANUS HENDERSON GROUP PLC Acquires Significant Stake in Pasithea Therapeutics Corp - GuruFocus
Pasithea Therapeutics (NASDAQ:KTTA) Upgraded at Zacks Research - Defense World
Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Did KTTA Stock Soar A Whopping 48% Today? - MSN
What is HC Wainwright’s Forecast for KTTA FY2025 Earnings? - Defense World
HC Wainwright Begins Coverage on Pasithea Therapeutics (NASDAQ:KTTA) - Defense World
There is no way Pasithea Therapeutics Corp (KTTA) can keep these numbers up - setenews.com
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright By Investing.com - Investing.com Nigeria
HC Wainwright & Co. Initiates Coverage of Pasithea Therapeutics (KTTA) with Buy Recommendation - Nasdaq
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com
HC Wainwright Initiates Coverage on Pasithea Therapeutics With Buy Rating, $3 Price Target - marketscreener.com
Is Pasithea Therapeutics Corp. stock attractive for hedge funds2025 Top Decliners & Technical Confirmation Trade Alerts - Newser
Small Cap Stocks To ConsiderNovember 30th - MarketBeat
Will Pasithea Therapeutics Corp. Equity Warrant stock benefit from commodity prices2025 Dividend Review & Weekly Top Performers Watchlists - Newser
Insiders Buying Pasithea Therapeutics Might Wish They Invested More, Stock Gains 10% - Yahoo Finance
Pasithea Therapeutics Reaches US$104m Market Cap Benefiting Insider Stock Buying - simplywall.st
Lawrence Steinman Bought 201% More Shares In Pasithea Therapeutics - Yahoo Finance
Will Pasithea Therapeutics Deliver On Clinical Promise Or Struggle With Funding Risks? - RTTNews
Top Biotech Stocks To Watch TodayNovember 29th - MarketBeat
Small Cap Stocks To Follow NowNovember 29th - MarketBeat
Best Small Cap Stocks To Keep An Eye OnNovember 28th - MarketBeat
Pasithea Therapeutics Completes $60M Public Offering - TipRanks
Best Penny Stocks To Watch TodayNovember 29th - MarketBeat
Pasithea Therapeutics announces closing of $60 million public offering of common stock - marketscreener.com
Pasithea Therapeutics (Nasdaq: KTTA) raises $60M, extends cash runway into 2028 - Stock Titan
Promising Penny Stocks To Consider – November 30th - Defense World
Small Cap Stocks To Consider – November 30th - Defense World
Published on: 2025-12-02 03:15:38 - Newser
Biotech Stocks To Watch Today – November 30th - Defense World
Pasithea Therapeutics (KTTA) Stock Analysis Report | Financials & Insights - Benzinga
Insider Buying Spree at Pasithea Therapeutics: Top Executives Invest Big! - TipRanks
Biotech Stocks To Watch TodayNovember 30th - MarketBeat
Pasithea Therapeutics Stock (KTTA) Opinions on PAS-004 Drug Updates - Quiver Quantitative
Pasithea therapeutics (KTTA) director Steinman buys $99,999 in stock By Investing.com - Investing.com Canada
Dumesnil Simon buys Pasithea Therapeutics (KTTA) shares By Investing.com - Investing.com Canada
Marques buys Pasithea Therapeutics (KTTA) shares worth $24999 By Investing.com - Investing.com Canada
Pasithea therapeutics (KTTA) director Steinman buys $99,999 in stock - Investing.com India
Dumesnil Simon buys Pasithea Therapeutics (KTTA) shares - Investing.com
Marques buys Pasithea Therapeutics (KTTA) shares worth $24999 - Investing.com
Pasithea Therapeutics Executives and Directors Make Significant Stock Purchases - TradingView — Track All Markets
Dir Dumesnil Buys 33,333 ($25K) Of Pasithea Therapeutics Corp [KTTA] - TradingView
Ready to Jump After Recent Trade: Pasithea Therapeutics Corp (KTTA) - Setenews
Pasithea Prices $60 Mln Offering To Advance PAS-004 And Broader Pipeline - Nasdaq
Top Biotech Stocks To Watch Today – November 29th - Defense World
Pasithea Therapeutics Reports Positive Phase 1 Data for PAS-004 - MSN
Pasithea Therapeutics Corp Stock (KTTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pasithea Therapeutics Corp Stock (KTTA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Marques Tiago | Chief Executive Officer |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
73,334 |
| Dumesnil Simon | Director |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
35,833 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):